Key result
Very severe aortic stenosis is linked to ~27% lower 1-year mortality after TAVR vs. severe AS.
Why the study?
Patients with very severe aortic stenosis carry a poorer prognosis than those with severe aortic stenosis, and although guidelines endorse earlier valve replacement, evidence supporting the safety and efficacy of TAVR in this subgroup remains limited.
Does transcatheter aortic valve replacement improve 1-year all-cause mortality and heart failure hospitalizations in patients with very severe aortic stenosis compared to patients with severe aortic stenosis?
Meta-Analysis (n=2,430)
Does transcatheter aortic valve replacement improve 1-year all-cause mortality and heart failure hospitalizations in patients with very severe aortic stenosis compared to patients with severe aortic stenosis?
Patients with very severe aortic stenosis experience lower 1-year all-cause mortality and heart failure readmissions following TAVR compared to those with severe aortic stenosis, without increased procedural complications.
Answers are grounded in this paper and cite their sources.
TAVR in VSAS linked to lower mortality and HF readmissions; extends observational data but leaves randomized confirmation open.
Background Patients with very severe aortic stenosis (VSAS) are regarded to carry a poorer prognosis than patients with severe aortic stenosis (SAS). While current guidelines endorse earlier aortic valve replacement, evidence supporting the safety and efficacy of transcatheter aortic valve replacement (TAVR) in this subgroup remains limited. This systematic review and meta-analysis aimed to clarify clinical outcomes following TAVR in VSAS patients. Methods From inception to March 2025, we systematically searched Medline, Embase, Scopus and Cochrane databases, for studies comparing TAVR outcomes in SAS and VSAS. Primary endpoints included 1-year all-cause mortality and heart failure hospitalizations. Secondary endpoints included procedural complications, and 30-day outcomes. Results Five observational studies including 2,430 patients (1,724 with SAS and 706 with VSAS) were analyzed. The mean age was 82.4 years, with 64.5% female. VSAS was associated with lower 1-year all-cause mortality (OR = 0.73; 95% CI: 0.57–0.94) and heart failure readmissions (OR = 0.57; 95% CI: 0.36–0.92). Stroke risk trended higher in VSAS (OR = 1.72; 95% CI: 0.87–3.40), while pacemaker implantation rates, degree of paravalvular leak, and 30-day mortality were comparable. Conclusions Patients with VSAS demonstrate greater benefit in terms of 1-year all-cause mortality and heart failure readmissions after TAVR compared to those with SAS, without an associated increase in procedural complications. Prospective studies with extended follow-up are required to validate these observations.
No takes yet. Share an insight, caveat, or question.
Avidan et al. (2026) conducted a meta-analysis in Very severe aortic stenosis vs severe aortic stenosis undergoing TAVR (n=2,430). Very severe aortic stenosis undergoing TAVR vs. Severe aortic stenosis undergoing TAVR was evaluated on 1-year all-cause mortality (co-primary with 1-year heart failure hospitalizations) (OR 0.73, 95% CI 0.57-0.94). Very severe aortic stenosis was associated with lower 1-year all-cause mortality and HF readmissions after TAVR vs severe aortic stenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: